Race Oncology Limited

Equities

RAC

AU000000RAC3

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 23:17:26 2024-06-04 EDT			5-day change	1st Jan Change
1.58 ^AUD	-1.56%		+9.34%	+88.10%

03-26	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
03-18	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Race Oncology at the heart of cancer care

August 09, 2023 at 03:02 pm

(via NewsDirect)

Race Oncology Ltd (ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks with Proactive soon after launching a new corporate strategy focused on maximising bisantrene’s anti-cancer and cardio-protective potential.

The company’s lead clinical focus will be on investigating anti-cancer, plus cardio-protective and FTO (fat mass and obesity-associated protein) properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer.

Clarke-Bruce said: “Race’s revised development program has been designed in such a way that our new bisantrene formulation can fit straight into a global pharmaceutical partner's pipeline.

“Through our rigorous clinical development plan, Race will investigate bisantrene RC220 in both metastatic breast cancer and continue our clinical experience in AML, while investigating and expanding our knowledge of its mechanism of action.

“We have a clear regulatory pathway and a program that is supported by international key opinion leaders, for a drug candidate which has already been shown to improve patients’ lives.”

Contact Details

Proactive Investors

Gregg Castano

+1 203-762-5649

gregg.castano@newsdirect.com

Latest news about Race Oncology Limited

Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	03-25	MT
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	03-17	CI
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	03-06	MT
Race Oncology Widens Loss in Fiscal H1	02-27	MT
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Race Oncology Names CEO; Shares Jump 5%	11-21	MT
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	11-21	CI
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	23-10-05	MT
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	23-09-18	CI
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Race Oncology Limited Announces Board Changes	23-08-21	CI
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	23-07-12	MT
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	23-07-12	CI
Race Oncology Signs Manufacturing Deal for Intravenous Formulation; Shares Fall 4%	23-07-11	MT
Race Oncology Limited Executes Global License Agreement with City of Hope to Access FTO IP	23-07-10	CI
Race Oncology Secures License Deal for Cancer Research Intellectual Property	23-07-10	MT
Race Oncology Limited Announces Board Changes	23-06-28	CI
Tranche Update on Race Oncology Limited's Equity Buyback Plan announced on June 9, 2022.	23-06-22	CI
Race Oncology Limited's Equity Buyback announced on June 9, 2022, has closed with 634,881 shares, representing 0.40% for AUD 1.28 million.	23-06-21	CI
Race Oncology Names Chief Medical Officer	23-05-09	MT
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023	23-05-08	CI
Race Oncology Releases Detailed Commercial Assessment for Zantrene's Market Potential; Shares Jump 7%	23-04-13	MT
Race Oncology Receives AU$1.5 Million R&D Tax Rebate	23-03-27	MT
Race Oncology Scientific Chief to Step Down; Shares Fall 10%	23-03-23	MT
Race Oncology Limited Announces Management Changes	23-03-23	CI

Chart Race Oncology Limited

Duration

Period

More charts

Company Profile

Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RACE ONCOLOGY LIMITED	+88.10%	187M
MODERNA, INC.	+46.19%	56.65B
IQVIA HOLDINGS INC.	-6.14%	39.44B
LONZA GROUP AG	+39.19%	39.03B
CELLTRION, INC.	-6.65%	26.86B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.75B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	19.03B
BIO-TECHNE CORPORATION	-0.35%	12.28B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.26B
MEDPACE HOLDINGS, INC.	+28.38%	12.04B

Other Biotechnology & Medical Research

Race Oncology Limited

Equities

RAC

AU000000RAC3

Biotechnology & Medical Research

Race Oncology at the heart of cancer care

Contact Details

Latest news about Race Oncology Limited

Chart Race Oncology Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research